drugset / Trial / NCT01107405

Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge

NCT01107405

Phase 2 Completed 101 enrolled Bausch & Lomb Incorporated
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study is to evaluate the efficacy of loteprednol etabonate ophthalmic base, compared to loteprednol etabonate ophthalmic suspension, and vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in a modified Conjunctival Allergen Challenge model and in an environmental model during pollen season. Comparisons will be made following 2 weeks of dosing.

Timeline

Start
2010-04
Primary completion
2010-05
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Loteprednol Etabonate Other / unclassified Other

Indications